ArticleFrontiers in pharmacology2026
Pharmacological characterization and nephroprotective potential of venoms from three egyptian scorpion species.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Scorpion venoms are complex natural mixtures rich in bioactive molecules with emerging pharmacological relevance. Drug-induced kidney injury, particularly from chemotherapy agents like Taxol® (paclitaxel), remains a significant clinical challenge. This study investigates the molecular composition, enzymatic activities, and potential nephroprotective effects of venoms from three Egyptian scorpion species (Leiurus quinquestriatus, Buthacus leptochelys, and Scorpio maurus palmatus) against Taxol®-induced kidney injury. Methods: Comprehensive molecular mass profiling of the three venoms was performed using liquid chromatography-mass spectrometry (LC-MS). Enzymatic characterization included assays for hyaluronidase, phospholipase A2 (PLA2), hemolytic, and antibacterial activities. The disulfide-bonded versus non-disulfide-bonded peptide (NDBP) ratios were also determined. To evaluate nephroprotective efficacy, the venoms were administered in an in vivo model of Taxol®-induced nephrotoxicity. Renal antioxidant defenses, oxidative stress markers, inflammatory responses, and histopathological architecture were assessed. Results: LC-MS revealed hundreds of venom components within the 500-9,000 Da range, indicating a high diversity of low-molecular-weight peptides. All venoms exhibited notable hyaluronidase activity, whereas PLA2 activity varied markedly: absent in L. quinquestriatus, low in B. leptochelys, and pronounced in S. m. palmatus. Minor hemolytic activity was observed only in B. leptochelys, and all venoms demonstrated weak antibacterial effects. The ratio of disulfide-bonded to non-disulfide-bonded peptides ranged from 7.5% NDBPs in L. quinquestriatus to 48% in S. m. palmatus. Despite these biochemical differences, all three venoms significantly attenuated Taxol-induced nephrotoxicity, as evidenced by restored renal antioxidant defenses, suppressed oxidative stress and inflammatory responses, and improved renal histopathological architecture. Discussion: The inverse correlation between PLA2 and hyaluronidase activities, coupled with striking differences in peptide composition, exemplifies a biochemical trade-off in venom resource allocation-highlighting how distinct molecular solutions evolve to meet similar ecological demands. From a pharmacological perspective, the comparable nephroprotective efficacy across species suggests that scorpion venoms contain bioactive constituents capable of modulating key molecular pathways involved in drug-induced renal injury. In a pharmacoepidemiologic context, these findings highlight the potential of venom-derived compounds as adjunctive or protective agents to mitigate chemotherapy-associated nephrotoxicity, supporting further investigation into their safety, efficacy, and translational applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.